Drupal.behaviors.print = function(context) {window.print();window.close();}>
MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth Launches ConfirmMDx
May 16, 2012
MDx/CDx Focus: NanoString Kicks off Second PAM50 Validation Study; MDxHealth Launches ConfirmMDx
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Personalized Medicine Highlights from San Antonio Breast Cancer Symposium 2012
December 12, 2012 / Pharmacogenomics Reporter
NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
December 14, 2011 / Pharmacogenomics Reporter
St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter
MDx/PGx Highlights from ASCO 2011
June 15, 2011 / Pharmacogenomics Reporter
With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter